Search results
Neprilysin as a Biomarker
Author(s):
Noemi Pavo
,
Suriya Prausmüller
,
Philipp E Bartko
,
et al
Added:
3 years ago
Article
Author(s):
Sam Hayman
,
John J Atherton
Added:
3 years ago
Heart failure (HF) is associated with significant morbidity and mortality and confers a major economic burden.1 Large randomised controlled trials (RCTs) have demonstrated that inhibition of the renin–angiotensin– aldosterone and sympathetic nervous systems improve outcomes in patients with HF and a reduced left ventricular ejection fraction (HFrEF) (see Figure 1),2–9 with clinical guidelines…
View more
Author(s):
Juan Tamargo
Added:
3 years ago
Chronic heart failure (HF) is a complex and progressive clinical syndrome resulting from any abnormality of cardiac structure or function. The American College of Cardiology Foundation/American Heart Association guideline defines HF as ‘a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood’.1 The European Society of…
View more
Author(s):
John JV McMurray
Added:
1 year ago
ESC Congress – Prof John McMurray (University of Glasgow, UK) joined us to discuss the finding of the PERSPECTIVE trial (NCT02884206).
The trial assessed whether the angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan (Novartis) has any negative impact on cognitive function in people who have heart failure with preserved ejection fraction (HFpEF) when compared with HFpEF…
View more
Author(s):
Noel S Lee
,
Lori B Daniels
Added:
3 years ago
Today, natriuretic peptides are ubiquitously utilized for the diagnosis, treatment, and prognostication of heart failure in the Emergency Department, as well as inpatient and outpatient settings alike.1–5 These endogenous hormones counteract some of the most detrimental effects of heart failure. Given their clinical and physiological importance, the fact that a manuscript describing the…
View more
Author(s):
Thomas G von Lueder
,
Dipak Kotecha
,
Dan Atar
,
et al
Added:
3 years ago
Heart Failure (HF) constitutes a major global health problem, evidenced by substantial morbidity and mortality, requiring enormous healthcare-related expenditure. HF is associated with high symptomatic burden, and with a relentless and progressive clinical course towards end-stage disease. A large body of epidemiological data suggests that the prognosis in HF is as poor as in advanced cancer.1…
View more
Antoni Bayés-Genís
Research Area(s) / Expertise:
Author
Expertise
Author(s):
David Morrow
Added:
4 years ago
In this video, Prof David A Morrow, Professor of Medicine and Cardiology from the Harvard Medical School, Boston, MA, US, discusses the emerging data on utilising Angiotensin Receptor-Neprilysin Inhibitor (ARNI) therapy in complex patients.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
This interview is a component of a wider Radcliffe Education programme entitled,'Review of emerging…
View more
Author(s):
Milton Packer
Added:
3 years ago
Patients with a broad range of systemic inflammatory rheumatic diseases (i.e. rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and ankylosing spondylitis) are exceptionally prone to cardiovascular disorders, but previous work concerning the development of heart disease in these individuals has largely focused on the risk of MI.
However, the most important cardiovascular…
View more
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article